BGS649

Phase 2Small molecule

MMereo BioPharma

BGS649 is one of 67 small molecule programs targeting Hypogonadotropic Hypogonadism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypogonadotropic HypogonadismActive, not recruiting

EndometriosisActive, not recruiting

Hypogonadotropic HypogonadismPhase 2

Active, not recruiting

EndometriosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Endometriosis

#DrugCompanyPhaseTrials

Orilissa

AbbVie

Phase 3

16 2

Lupron

AbbVie

Phase 3

1 3

Revia

Teva

Phase 3

1 4

Leuprorelin

Takeda

Phase 3

8 5

Orgovyx

Sumitomo Pharma America, Inc.

Phase 3

3 6

Trental

VValidus Pharmaceuticals

Phase 3

1 7

Lupron

EEastern Cooperative Oncology Group

Phase 3

1 8

Firmagon

Ferring

Phase 3

1 9

Estradiol/norethindrone Acetate

AbbVie

Phase 3

5 10

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypogonadotropic Hypogonadism1 trial

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

Completed·MMereo BioPharma·Phase 2·NCT02730169·271 enrolled

Endometriosis1 trial

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Terminated·MMereo BioPharma·Phase 2·NCT01116440·27 enrolled

Unspecified1 trial

A 6 Month Safety Extension Study of MBGS205

Completed·MMereo BioPharma·Phase 2·NCT02908074·143 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BGS649. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGS649 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGS649. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mereo BioPharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMereo BioPharma

BGS649

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypogonadotropic Hypogonadism1 trial

Endometriosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News